Abstract 72P
Background
The working space in the submucosal tunnel of endoscopic submucosal tunnel technique (ESTT) is limited, and the visual field is obscure during close inspection or hemostasis. This retrospective study aimed to evaluate the efficacy and safety of a novel near-focus mode technique for accurate operation during the submucosal tunneling endoscopic procedure.
Methods
A retrospective two-center study was designed. A total of 51 patients undergoing ESTT procedures with near-focus mode (n = 29) or traditional mode (n = 22) between February 2016 and May 2019 were included in this study. Data regarding the efficacy, complications, hospital stay period, and other parameters were recorded.
Results
When using the near-focus mode during the ESTT procedure, it is convenient to acquire a clear image and accurate operation. The clinical success rate was 100% (29/29) in near-focus group, higher than that in traditional group (90.9%, 20/22), although the difference was not significant (P = 0.181). The adverse event occurred more frequently in traditional group (45.5%) compared to that in the near-focus group (17.2%, P = 0.036). Especially, the near-focus group exhibited a significantly lower rate of bleeding compared to that of the traditional group (0 vs 18.2%, P = 0.029). Furthermore, the mean hospital stay after procedure was shorter in near-focus group (5.7 days) than that in traditional group (6.7 days, P = 0.013).
Conclusions
The visual field is more clearly exposed within submucosal tunneling by using near-focus mode than traditional procedures. The efficacy and safety of this novel technique was proved in our procedures.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Xiangsheng Fu.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
259P - The BOT patients fail to benefit from surgical staging procedures in prognosis and fertility outcomes: A retrospective analysis
Presenter: Li Na
Session: Poster display session
Resources:
Abstract
260P - Malignant ovarian germ cell tumours (MOGCT): Treatment results of 149 pts
Presenter: Dzhennet Chekini
Session: Poster display session
Resources:
Abstract
261P - Ovarian germ cell tumours - challenges and outcomes from a tertiary care centre in South India
Presenter: Vishnu Sreedath
Session: Poster display session
Resources:
Abstract
262P - Gestational trophoblastic tumours: Experience of the medical oncology department Hassan II University Hospital-Morocco about 29 cases
Presenter: Karima Oualla
Session: Poster display session
Resources:
Abstract
263TiP - ATHENA (GOG-3020/ENGOT-ov45): A randomised, double-blind, placebo-controlled phase III study of the poly (ADP-ribose) polymerase (PARP) inhibitor rucaparib + the PD-1 inhibitor nivolumab following frontline platinum-based chemotherapy in ovarian cancer
Presenter: Keiichi Fujiwara
Session: Poster display session
Resources:
Abstract
264TiP - ENGOT-ov43/KEYLYNK-001: A phase III trial of pembrolizumab plus chemotherapy with olaparib maintenance for first-line treatment of BRCA¬-nonmutated advanced epithelial ovarian cancer
Presenter: Keiichi Fujiwara
Session: Poster display session
Resources:
Abstract
265TiP - KEYNOTE-826: A phase III randomized study of chemotherapy with or without pembrolizumab for first-line treatment of persistent, recurrent, or metastatic cervical cancer
Presenter: Keiichi Fujiwara
Session: Poster display session
Resources:
Abstract
271P - Comparison between CHOP like regimens and DAEPOCH with or without Rituximab in adult high grade B cell lymphoma NOS; A retrospective study from a tertiary cancer hospital in South India
Presenter: LALATENDU MOHARANA
Session: Poster display session
Resources:
Abstract
272P - Melatonin increases the chemosensitivity of diffuse large Bell lymphoma cells to Epirubicin by inhibiting P-glycoprotein expression via the NF-κB pathway
Presenter: Xiuhua Sun
Session: Poster display session
Resources:
Abstract
273P - MALT1- A20 and NF-κB expression pattern in patients with non-Hodgkin lymphomas
Presenter: Alshimaa Alhanafy
Session: Poster display session
Resources:
Abstract